Cargando…

Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies

Conventional chemotherapy-based drug combinations have, until recently, been the backbone of most therapeutic strategies for cancer. In a time of emerging rationale drug development, targeted therapies are beginning to be added to traditional chemotherapeutics to synergistically enhance clinical res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lewis, Alexander C., Wallington-Beddoe, Craig T., Powell, Jason A., Pitson, Stuart M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060109/ https://www.ncbi.nlm.nih.gov/pubmed/30062053 http://dx.doi.org/10.1038/s41420-018-0075-0

Ejemplares similares

Author Correction: Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies
por: Lewis, Alexander C., et al.
Publicado: (2021)

Novel therapies for multiple myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017)

Enhancing ER stress in myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017)

The sphingosine 1-phosphate receptor 2/4 antagonist JTE-013 elicits off-target effects on sphingolipid metabolism
por: Pitman, Melissa R., et al.
Publicado: (2022)

Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies
por: Mynott, Rachel L., et al.
Publicado: (2023)

Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma
por: Tea, Melinda N., et al.
Publicado: (2020)

Targeting the integrated stress response in hematologic malignancies
por: Nwosu, Gus O., et al.
Publicado: (2022)

Targeting Metabolism and Autophagy in the Context of Haematologic Malignancies
por: Banerji, Versha, et al.
Publicado: (2012)

Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017)

Role of Sphingolipids and Metabolizing Enzymes in Hematological Malignancies
por: Kitatani, Kazuyuki, et al.
Publicado: (2015)

Prognostic and predictive biomarker developments in multiple myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2021)

Targeting hypoxia in solid and haematological malignancies
por: Harris, Bill, et al.
Publicado: (2022)

Targeting Sphingolipids for Cancer Therapy
por: Companioni, Osmel, et al.
Publicado: (2021)

Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition
por: Bennett, Melissa K., et al.
Publicado: (2021)

Gene Therapy of Sphingolipid Metabolic Disorders
por: Shaimardanova, Alisa A., et al.
Publicado: (2023)

Membrane engineering of S. cerevisiae targeting sphingolipid metabolism
por: Lindahl, Lina, et al.
Publicado: (2017)

Potential therapeutic targets for atherosclerosis in sphingolipid metabolism
por: Yu, Zemou, et al.
Publicado: (2019)

Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies
por: Xiao, Xinyi, et al.
Publicado: (2022)

Improving TCR Gene Therapy for Treatment of Haematological Malignancies
por: Nicholson, Emma, et al.
Publicado: (2012)

Survival of critically ill patients with haematological malignancies compared with patients without haematological malignancy
por: Pugh, R, et al.
Publicado: (2013)

Modification of the tumour microenvironment via exosomal shedding of sphingosine 1-phosphate receptor 2 by breast cancer cells
por: Pitson, Stuart M., et al.
Publicado: (2018)

PSYCHOLOGICAL ASPECTS OF HAEMATOLOGICAL MALIGNANCIES
por: Kulhara, P., et al.
Publicado: (1990)

Tuberculosis in Patients with Haematological Malignancies
por: Anibarro, Luis, et al.
Publicado: (2014)

Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network
por: Smith, A, et al.
Publicado: (2011)

Editorial: New immunotherapeutic and pharmacological targets and strategies in haematological malignancies
por: Williams, Mark Thomas Shaw, et al.
Publicado: (2023)

A Comprehensive Review: Sphingolipid Metabolism and Implications of Disruption in Sphingolipid Homeostasis
por: Quinville, Brianna M., et al.
Publicado: (2021)

Antineoplastic Agents Targeting Sphingolipid Pathways
por: Kroll, Alexander, et al.
Publicado: (2020)

T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
por: Mehta, Palak H., et al.
Publicado: (2021)

Computational modeling of sphingolipid metabolism
por: Wronowska, Weronika, et al.
Publicado: (2015)

Autophagy in the light of sphingolipid metabolism
por: Harvald, Eva Bang, et al.
Publicado: (2015)

Sphingolipid Metabolism in Systemic Inflammation
por: Deigner, H. P., et al.
Publicado: (2007)

Sphingolipid Metabolism in Systemic Inflammation
por: Deigner, H. P., et al.
Publicado: (2007)

Editorial: Sphingolipid metabolism and cancer
por: Ivanova, Margarita M., et al.
Publicado: (2022)

Sphingolipids in neuroinflammation: a potential target for diagnosis and therapy
por: Lee, Ju Youn, et al.
Publicado: (2020)

Antileishmanial Activity of Tamoxifen by Targeting Sphingolipid Metabolism: A Review
por: Zewdie, Kaleab Alemayehu, et al.
Publicado: (2022)

Targeting Sphingolipid Metabolism as a Therapeutic Strategy in Cancer Treatment
por: Janneh, Alhaji H., et al.
Publicado: (2022)

Advancements on the Multifaceted Roles of Sphingolipids in Hematological Malignancies
por: Raza, Yasharah, et al.
Publicado: (2022)

Expression of testicular genes in haematological malignancies
por: Lim, S H, et al.
Publicado: (1999)

Clinical use of rituximab in haematological malignancies
por: Avivi, I, et al.
Publicado: (2003)

The Role of miRNA in Haematological Malignancy
por: Gounaris-Shannon, Stephanie, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_hlcv9gns8eqicqqvvuup2q30ts